ACAAI

DBV Technologies to Present New Data at ACAAI 2023

Retrieved on: 
Thursday, November 2, 2023
Aurora, Panel discussion, FDA, American College, DBV, Food, Biologics license application, ACAAI, Safety, European Medicines Agency, MBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, PST, Immune system, Risk, Asthma, DRS, DBV Technologies, Allergy, Children's Hospital Colorado, Patient, BLA, Pharmaceutical industry, Vaccine, Euronext

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
  • The presentation will be available on DBV’s website, www.dbv-technologies.com , following the conclusion of the meeting for those who are unable to attend.
  • In addition, DBV is a 2023 ACAAI Benefactor Level Corporate Council Member.
  • The Company will also host a booth in the ACAAI Exhibit Hall from Saturday, November 11 – Monday, November 13th.

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

Retrieved on: 
Monday, October 30, 2023
HAE, ACAAI, Abstract, EST, American College, PST, Anaheim Convention Center, Hereditary angioedema, American College of Allergy, Asthma and Immunology, Pharmaceutical industry, Mobile phone

ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.

Key Points: 
  • ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.
  • On November 9 at 8:30 a.m. PST (11:30 a.m. EST), the ePosters and accompanying audio voice-overs will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ACAAI, University, Allergy, American College, PST, American College of Allergy, Asthma and Immunology, Therapy, Asthma, Internal medicine, Hereditary angioedema, Pharmaceutical industry, Immunology

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST.

Key Points: 
  • Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST.
  • Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present additional data from the Phase 1a clinical trial of STAR-0215 in a poster titled, “Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results” at 12:35pm PST in the ePoster Section – Exhibit Hall, Monitor 12, presentation number P066.

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Retrieved on: 
Thursday, November 2, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Princess, Patient, Them, Q&A, American College, KALV, Monitor, ACAAI, HAE, Real, Convention, Abstract, Hereditary angioedema, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13.
  • The presentations are:
    Understanding Why Hereditary Angioedema Patients Often Do Not Carry Their On-Demand Treatment with Them - #P078: Bob Geng, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Cristine Radojicic.
  • Results shared as an oral poster presentation and Q&A on Friday, November 10 from 4:30 - 4:45 pm PT at Monitor 13
    Treatment of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real-World ACARE Survey - #P059: Marcus Maurer, Markus Magerl, Marc A. Riedl, Sherry Danese, Julie Ulloa, Vibha Desai, Paul K. Audhya.
  • Results shared as an oral poster presentation and Q&A on Sunday, November 12 from 12:20 - 12:35 pm PT at Monitor 13
    All poster presentations will take place in the ePoster Section of the Exhibit Hall.

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Retrieved on: 
Friday, October 27, 2023
American College, Anaheim Convention Center, ACAAI, RESEARCH, Hereditary angioedema, HAE, BioCryst Pharmaceuticals, Convention, Abstract, PARK, Pharmaceutical industry, Nightclub, Patient

RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).
  • The meeting will take place at the Anaheim Convention Center in Anaheim, Calif., from November 9-13, 2023.
  • Berotralstat Reduced Attack Rates in Patients with Hereditary Angioedema with Normal C1-Inhibitor: Real-World Outcomes; ePoster #P082; Friday, November 10, 5:30-5:45 p.m. PT; Monitor #13, Exhibit Hall
    Berotralstat Reduced Attack Rates Compared to Baseline in Patients with Hereditary Angioedema in APeX-S; ePoster #P064; Saturday, November 11, 12:05-12:20 p.m. PT; Monitor #12, Exhibit Hall
    In addition to displaying in the exhibit hall at the noted times, ePosters will be accessible online and on demand to registered attendees on Thursday, November 9, beginning at 8:00 a.m. PT on ACAAI’s website.

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
ACAAI, PD, Allergy, Emergency, Investment, ARS, New Drug Application, European Medicines Agency, Clinical trial, NDA, Pharmacokinetics, American Academy, G&A, American Academy of Allergy, Asthma, and Immunology, Marketing, EMA, Pain, Asthma, Patient, Nature, Adrenaline, Rhinitis, SAN, OTC, PDUFA, AAAAI, R, MAA, Research, Caregiver, FDA, American College, Regulation of tobacco by the U.S. Food and Drug Administration, Treatment, Food, American College of Allergy, Asthma and Immunology, D, Vaccine, Pharmaceutical industry, Anaphylaxis

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • We believe we are well on our way to achieving this goal,” said Richard Lowenthal, president and chief executive officer of ARS Pharmaceuticals.
  • R&D Expenses: Research and development (R&D) expenses were $4.7 million for the quarter ended December 31, 2022, and $18.4 million for the year ended December 31, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $10.7 million for the quarter ended December 31, 2022, and $18.5 million for the year ended December 31, 2022.
  • Net Loss: Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

Retrieved on: 
Tuesday, March 7, 2023
Sale, Growth, Food, Patent, American College of Allergy, Asthma and Immunology, Adrenaline, American Academy of Allergy, Asthma, and Immunology, United States Food Administration, FDA, NDA, Therapy, ATM, Trial of the century, PK, American Academy, Depreciation, AAAAI, Research, Asthma, Anaphylaxis, Tax, ACAAI, American College, EBITDA, Allergy, Plasma, Patient, Emergency, Community, Agreement, Absorption, Epilepsy, Cryptocurrency, Pharmaceutical industry, Video game, Bookkeeping, Clobazam

“Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Aquestive anticipates providing a revised pivotal study protocol to the FDA in the second quarter 2023 and starting the pivotal study in the third quarter 2023.
  • Total revenues were $10.7 million in the fourth quarter 2022, compared to $11.1 million in the fourth quarter 2021, a decrease of 4%.
  • During the fourth quarter 2022, the Company accessed capital net proceeds of $0.9 million under its “At-the-Market” (ATM) facility.

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Tuesday, March 7, 2023
PDUFA, New Drug Application, Sinusitis, Reopening Ontario Act, Conference call, FDA, ENT, Safety, Telephone, Ear, Webcast, OPTN, Nose, Research, ACAAI, American College, Marketing, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, MPH, Exhalation delivery system, Exhalation, Food, GAAP, Pharmaceutical industry, Cryptocurrency, Conference, MD

YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2022, and provided recent operational highlights.

Key Points: 
  • Assuming acceptance and a standard review period the Company expects the FDA's PDUFA action date to be in December 2023.
  • For the three-month and twelve-month periods ended December 31, 2022, research and development expenses were $2.9 million and $15.3 million, respectively.
  • The net loss for the three-month period ended December 31, 2022 was $15.1 million, or $0.17 per share (basic and diluted).
  • The net loss for the twelve-month period ended December 31, 2022 was $74.8 million, or $0.87 per share (basic and diluted).

Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, December 8, 2022
Asthma, R, Intellectual property, Annual report, PD, Research, Absorption, Softgel, Bradykinin, Food, FDA, Attack, Book, Record, ACAAI, Safety, Executive Committee, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hereditary angioedema, Trial of the century, American College of Allergy, Asthma and Immunology, Human, International Accounting Standards Board, Security (finance), Research and development, American College, HAE, Union, Patient, Association of International Accountants, Human resources, Administration, Degenerative disease, COVID-19, Pharmaceutical industry, Vaccine

Today Pharvaris announced top-line Phase 2 data demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.

Key Points: 
  • Today Pharvaris announced top-line Phase 2 data demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.
  • R&D expenses were €14.1 million for the quarter ended September 30, 2022, compared to €9.0 million for the quarter ended September 30, 2021.
  • G&A expenses were €8.3 million for the quarter ended September 30, 2022, compared to €4.4 million for the quarter ended September 30, 2021.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

Retrieved on: 
Thursday, December 8, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fiscal year, Security (finance), Form 10-K, Hereditary angioedema, American College, Conference, NDA, Risk, Metabolism, ACAAI, Research, Patient, KALV, HAE, D, FDA, Mental health, Quality of life, Attack, COVID-19, Absorption, Journal, DME, Annual report, Safety, Diabetic retinopathy, ODT, Medicinal chemistry, Pharmaceutical industry

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.
  • Second Fiscal Quarter and Recent Business Highlights:
    Presented at both the Stifel 2022 Healthcare Conference and the Jefferies London Healthcare Conference.
  • Second Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended October 31, 2022 or October 31, 2021.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need.